Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $51,306.08 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,064 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $51,306.08. Following the completion of the transaction, the senior vice president now owns 4,232 shares in the company, valued at $204,067.04. This represents a 20.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total value of $117,750.00.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM traded up $1.62 during midday trading on Tuesday, reaching $50.21. The company’s stock had a trading volume of 410,214 shares, compared to its average volume of 511,828. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $50.34. The company has a market capitalization of $2.41 billion, a P/E ratio of -24.86 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business’s fifty day simple moving average is $44.39 and its 200-day simple moving average is $42.02.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same period last year, the company posted ($0.57) earnings per share. The firm’s quarterly revenue was up 89.4% compared to the same quarter last year. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MIRM has been the topic of several analyst reports. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Leerink Partners increased their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Citigroup increased their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Buy” and a consensus target price of $57.10.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in MIRM. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares in the last quarter. R Squared Ltd acquired a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $69,000. Avanza Fonder AB acquired a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $189,000. Y Intercept Hong Kong Ltd acquired a new stake in Mirum Pharmaceuticals in the third quarter worth about $215,000. Finally, Creative Planning acquired a new stake in Mirum Pharmaceuticals in the third quarter worth about $249,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.